Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutics, Inc. - Common Stock
(NQ:
HALO
)
64.63
+2.50 (+4.02%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 31, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Halozyme Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
↗
August 26, 2025
Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday.
Via
Investor's Business Daily
Topics
ETFs
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Stands Out as a Top Undervalued Stock with Strong Fundamentals
↗
August 20, 2025
Discover HALOZYME (HALO), a top value investing pick. It boasts a strong Valuation Rating of 9, high profitability, and robust growth, making it a fundamentally sound yet undervalued stock.
Via
Chartmill
What 7 Analyst Ratings Have To Say About Halozyme Therapeutics
↗
August 18, 2025
Via
Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Top Pick for Affordable Growth Investors
↗
August 15, 2025
HALOZYME THERAPEUTICS (HALO) offers affordable growth with strong revenue, EPS expansion, and undervalued metrics, blending value and growth investing principles.
Via
Chartmill
What Does the Market Think About Halozyme Therapeutics?
↗
August 07, 2025
Via
Benzinga
Earnings Scheduled For August 5, 2025
↗
August 05, 2025
Via
Benzinga
Earnings Outlook For Halozyme Therapeutics
↗
August 04, 2025
Via
Benzinga
What's Driving the Market Sentiment Around Halozyme Therapeutics?
↗
May 28, 2025
Via
Benzinga
Price Over Earnings Overview: Halozyme Therapeutics
↗
May 28, 2025
Via
Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Fits Louis Navellier’s High-Growth Stock Criteria
↗
August 06, 2025
Louis Navellier’s *The Little Book That Makes You Rich* outlines 8 key factors for identifying high-growth stocks like HALOZYME THERAPEUTICS (HALO), which excels in earnings, sales, margins, and ROE....
Via
Chartmill
Halozyme (HALO) Q2 EPS Jumps 69%
↗
August 05, 2025
Via
The Motley Fool
Topics
Intellectual Property
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Shows Strong Growth Momentum and Technical Breakout Potential
↗
July 30, 2025
HALOZYME THERAPEUTICS INC (HALO) shows strong earnings growth, rising profit margins, and bullish technicals, making it a high-growth momentum stock to watch.
Via
Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO) Stands Out as a Strong Undervalued Stock with Solid Fundamentals
↗
July 25, 2025
Halozyme Therapeutics (HALO) is an undervalued biotech stock with strong fundamentals, low P/E ratios, high profitability, and solid growth potential, making it a compelling pick for value investors.
Via
Chartmill
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
↗
July 22, 2025
Via
Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Contender in Affordable Growth Stocks
↗
July 21, 2025
HALOZYME THERAPEUTICS (NASDAQ:HALO) shows strong growth, solid profitability, and reasonable valuation, making it an interesting affordable growth stock in the biotech sector.
Via
Chartmill
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years
↗
July 07, 2025
Via
Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors
↗
June 28, 2025
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and reasonable valuation, making it a standout in affordable growth investing.
Via
Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Biotech Stock With Strong Fundamentals and Attractive Valuation
↗
June 25, 2025
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers a rare mix of strong growth, profitability, and financial health at an attractive valuation, making it a standout in the biotech sector.
Via
Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Strong Growth Stock with Technical Breakout Potential
↗
June 17, 2025
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) shows strong growth fundamentals and a potential technical breakout, making it a stock to watch in the biotech sector.
Via
Chartmill
Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today
↗
June 12, 2025
Via
Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors
↗
June 07, 2025
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and an attractive valuation, making it a standout in the biotech sector for investors seeking affordable growth...
Via
Chartmill
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years
↗
June 04, 2025
Via
Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Biotech Stock With Strong Fundamentals and Attractive Valuation
↗
June 03, 2025
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong profitability, financial health, and growth at an attractive valuation, making it a potential value opportunity in biotech.
Via
Chartmill
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
↗
May 24, 2025
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and a look at what's drivin the interest.
Via
Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors
↗
May 17, 2025
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and an attractive valuation, making it a standout in the biotech sector for investors seeking affordable growth...
Via
Chartmill
Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday
↗
May 16, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
May 13, 2025
Via
Benzinga
Crude Oil Gains 3%; US Inflation Eases In April
↗
May 13, 2025
Via
Benzinga
Topics
Economy
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
May 13, 2025
Via
Benzinga
There are notable gap-ups and gap-downs in today's session.
↗
May 13, 2025
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.